Literature DB >> 6206243

A human monoclonal antibody reactive with human prostate.

D H Lowe, H H Handley, J Schmidt, I Royston, M C Glassy.   

Abstract

A human immunoglobulin M monoclonal antibody secreting hybridoma, termed MHG7, has been isolated and characterized for its reactivity against human prostate cells. Lymphocytes isolated from a regional draining lymph node of a patient with prostate carcinoma were fused with murine P3-NS1-Ag4-1 myeloma cells. Supernatants from the generated mouse-human somatic cell hybrids were first screened for human immunoglobulin production by an enzyme immunoassay. The identified human immunoglobulin-secreting hybridomas were expanded for further analysis and their supernatants screened by enzyme immunoassay against a panel of prostate cell lines. The human immunoglobulin M monoclonal antibody MHG7, in addition to reacting with prostate cell lines, also reacted with prostate carcinoma cells and benign prostatic hypertrophy cells on both frozen and paraffin embedded tissue sections. These data suggest that regional draining lymph nodes of prostate carcinoma patients can be used as a source of human lymphocytes for generating human immunoglobulin-secreting hybridomas reactive with human prostate cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6206243     DOI: 10.1016/s0022-5347(17)49872-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  Growth of human-human hybridomas in serum-free media enhances antibody secretion.

Authors:  M C Glassy; R E Peters; A Mikhalev
Journal:  In Vitro Cell Dev Biol       Date:  1987-11

2.  Biochemical and immunological characterizations of antigens recognised by human monoclonal antibodies.

Authors:  A Imam; C R Taylor
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

3.  Detection by a human monoclonal antibody of a glycoprotein associated with malignant proliferation of mammary epithelial cells.

Authors:  S A Imam; L A Mills; C R Taylor
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.